Study-related procedures at each study visit
| Procedures | Visits | Delivery | |||||
| Visit −2 | Visit −1 | Visit 0 | Visit 1 | Visit 2 | Visit 3 | ||
| Screening ≤16 weeks | Run-in-phase ≤17 weeks | Randomisation Week ≤18 | Week 18–20 | Week 26–28 | Week 32 | ||
| Informed consent | X | ||||||
| Eligibility assessment | X | ||||||
| Demographics | X | ||||||
| History | X | ||||||
| Height | X | ||||||
| Weight | X | X | X | X | X | X | X |
| Blood pressure | X | X | X | X | X | X | X |
| Antenatal examination | X | X | X | X | X | X | |
| Dairy consumption questionnaire | X | X | X | X | X | ||
| Barriers questionnaire | X | X | |||||
| Baseline PA monitoring with Vivofit 4 | X | ||||||
| PA step-count monitoring | X | X | X | X | |||
| Randomisation | X | ||||||
| OGTT | X | X | |||||
| Dating scan | X | ||||||
| Morphology scan | X | ||||||
| Ultrasound scan (growth) | X | ||||||
| Fasting plasma glucose | X | ||||||
| Intrapartum assessment (mother) | X | ||||||
| New born assessment | X | ||||||
OGTT, oral glucose tolerance test; PA, physical activity.